Ph.D., Associate Research Scientist
swedish dental AB
Svalbard and Jan Mayen
He is an Associate Research Scientist at Columbia University in New York City, where he explores the chemistry and pharmacology of novel psychoactive compounds that hold promise as therapeutics for pain, depression, and anxiety. He is an expert in the field of opioid receptor modulators and coordinates multi-disciplinary collaborations in this area across multiple research institutions. As one aspect of his work, he has extensively studied the alkaloids of Mitragyna speciosa (kratom). Dr. Kruegel has recently published the first detailed characterization of the molecular signaling properties of Mitragyna alkaloids and continues to work with these compounds to develop new, safer analgesics. His work in medicinal chemistry has led to inventorship on multiple patent applications, both for Mitragyna alkaloids and other molecular scaffolds. Dr. Kruegel is also a biopharmaceutical entrepreneur and co-founder of Kures Inc., a seed-stage startup company dedicated to the development of new therapeutics for treatment-resistant depression. Prior to his current work, Dr. Kruegel completed postdoctoral studies and his doctoral degree at Columbia University in the field of medicinal chemistry and previously obtained a Bachelors of Science in chemistry from Stevens Institute of Technology in New Jersey.